Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.

Autor: Araki D; Department of Medicine, Residency Program, University of Washington, Seattle, Washington., Redman MW; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Martins R; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Eaton K; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Baik C; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Chow L; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Goulart B; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Lee S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Santana-Davila R; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington., Liao J; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Radiation Oncology, University of Washington, Seattle, Washington., Parvathaneni U; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Radiation Oncology, University of Washington, Seattle, Washington., Laramore G; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Radiation Oncology, University of Washington, Seattle, Washington., Futran N; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington., Mendez E; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington., Bhrany A; Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, Washington., Rodriguez CP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
Jazyk: angličtina
Zdroj: Head & neck [Head Neck] 2016 Sep; Vol. 38 (9), pp. 1318-23. Date of Electronic Publication: 2016 Apr 07.
DOI: 10.1002/hed.24437
Abstrakt: Background: Postoperative cisplatin and radiation is the standard of care for high-risk squamous cell carcinoma of the head and neck (SCCHN). We have used cetuximab and radiation in the postoperative setting for patients deemed poor candidates for cisplatin.
Methods: We retrospectively identified 40 patients who received cetuximab and radiation for resected locoregionally advanced SCCHN between 2006 and 2013 at our institution.
Results: The 2-year Kaplan-Meier estimates were: overall survival (OS) 41%, recurrence-free survival (RFS) 34%, locoregional control 63%, and distant metastatic control 59%. Eastern Cooperative Oncology Group (ECOG) performance status ≥1 predicted for inferior OS (hazard ratio [HR] = 5.43; p = .003), RFS (HR = 4.07; p = .007), and locoregional control (HR = 4.92; p = .04) in multivariate analysis.
Conclusion: Patients with resected high-risk SCCHN treated with postoperative cetuximab and radiation have suboptimal therapeutic outcomes. Further study of the efficacy and cost-effectiveness compared to radiation alone is warranted. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1318-1323, 2016.
(© 2016 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: